Publications by authors named "A T Volkova"
Article Synopsis
- Axatilimab is a monoclonal antibody that targets CSF-1R, approved for treating chronic graft-versus-host disease (cGVHD) and being researched for other conditions like idiopathic pulmonary fibrosis.
- A study involving 325 participants investigated the drug's pharmacokinetics (PK) and pharmacodynamics (PD), showing that it reduces certain immune cell levels, which affects enzyme levels in the bloodstream.
- The final PK/PD model, based on complex math involving differential equations, identified several factors influencing axatilimab's effectiveness and helped shape dosing strategies for cGVHD patients.
Background: The use of mobile technology to meet health needs, widely referred to as mobile health (mHealth), has played a critical role in providing self-management support for chronic health conditions. However, despite its potential benefits, mHealth technologies such as self-management support apps for spinal cord injury (SCI) have received little research attention, and an understanding of their public availability is lacking. Therefore, an overview of these apps is needed to complement findings from the literature for a complete understanding of mHealth self-management support tools for SCI to support the selection and improvement of existing apps and the development of new ones.
View Article and Find Full Text PDFData are accumulating on the hydrolytic activity of serum albumin towards esters and organophosphates. Previously, with the help of the technology of proton nuclear magnetic resonance (H NMR) spectroscopy, we observed the yield of acetate in the solution of bovine serum albumin and -nitrophenyl acetate (NPA). Thus, we showed that albumin possesses true esterase activity towards NPA.
View Article and Find Full Text PDFThe research & development (R&D) of novel therapeutic agents for the treatment of autoimmune diseases is challenged by highly complex pathogenesis and multiple etiologies of these conditions. The number of targeted therapies available on the market is limited, whereas the prevalence of autoimmune conditions in the global population continues to rise. Mathematical modeling of biological systems is an essential tool which may be applied in support of decision-making across R&D drug programs to improve the probability of success in the development of novel medicines.
View Article and Find Full Text PDFAims: To develop a model-informed methodology for the optimization of the Major Adverse Cardiac Events (MACE) composite endpoint, based on a model-based meta-analysis across anti-hypercholesterolemia trials of statin and anti-PCSK9 drugs.
Methods And Results: Mixed-effects meta-regression modeling of stand-alone MACE outcomes was performed, with therapy type, population demographics, baseline and change over time in lipid biomarkers as predictors. Randomized clinical trials up to June 28, 2022, of either statins or anti-PCSK9 therapies were identified through a systematic review process in PubMed and ClinicalTrials.